|
Volumn 34, Issue 6, 2013, Pages 831-839
|
Drug development status for Alzheimer's disease: Present scenario
|
Author keywords
Alzheimer's disease; Clinical trials; Dementia; Phase I; Phase II; Phase III
|
Indexed keywords
(7 CHLORO N QUINUCLIDIN 3 YL)BENZO[B]THIOTHIOPHENE 2 CARBOXAMIDE;
AMYLOID BETA PROTEIN[1-40];
AMYLOID PRECURSOR PROTEIN;
AVAGACESTAT;
AVP 923;
AZD 1446;
BAPINEUZUMAB;
BETA SECRETASE;
CRENEZUMAB;
DEXTROMETHORPHAN;
DIMEBON;
DONEPEZIL;
EHT 0202;
ETAZOLATE;
EVP 6124;
GAMMA SECRETASE;
GAMMA SECRETASE INHIBITOR;
GONADORELIN RECEPTOR;
GSK 933776;
ISPRONICLINE;
MK 0249;
NOOTROPIC AGENT;
PF 4494700;
PLACEBO;
PONEZUMAB;
PRX 03140;
QUINIDINE SULFATE;
RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
RILAPLADIB;
SEMAGACESTAT;
SOLANEZUMAB;
TARENFLURBIL;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VP 4896;
ALZHEIMER DISEASE;
DISEASE SEVERITY;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG RECEPTOR BINDING;
DRUG RESEARCH;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG TREATMENT FAILURE;
DRUG WITHDRAWAL;
EDEMA;
HUMAN;
PATHOGENESIS;
REVIEW;
SINGLE DRUG DOSE;
STUDY DESIGN;
SYMPTOM;
SYSTEMATIC REVIEW;
TREATMENT RESPONSE;
VASOGENIC EDEMA;
ALZHEIMER DISEASE;
ANTIPSYCHOTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG DESIGN;
HUMANS;
|
EID: 84879118825
PISSN: 15901874
EISSN: 15903478
Source Type: Journal
DOI: 10.1007/s10072-013-1316-x Document Type: Review |
Times cited : (30)
|
References (23)
|